Conference abstract · 19 Jun 2017
Conference abstractPublished 2018
Treatment outcomes of people living with Human Immunodeficiency Virus on highly active anti-retroviral therapy in Ethiopia: Does non-communicable disease(s) co-morbidities matters?
Jimma University, Ethiopia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The life expectancy of people living with human immunodeficiency virus (HIV) has dramatically improved with the much increased access to antiretroviral therapy. Consequently, a larger number of people living with HIV are living longer and facing the increased burden of non-communicable diseases. Objective: To assess effect of chronic disease(s) co-morbidities and determinants of treatment outcomes among HIV infected patients on highly active anti-retroviral therapy at Jimma University Medical Center. Methods: A nested case–control study was conducted among people living with HIV at Jimma University Medical Center from February 20 to August 20, 2016. Patient specific data was collected using structured data collection tool to identify relevant information and also patient reported outcome quality of life–HIV (PROQOL-HIV) scale was used to assess health related quality of life of patient. Data was analyzed using Statistical package for Social Science version 20.0. Logistic and linear regressions were done to identify factor associated to outcomes. Statistical significance was considered at p-value <0.05. Results: A total of 160 participants, 80 cases and 80 controls, were included in the analysis. Among cases hypertension accounts 13.8%, followed by diabetes (11.9%) and about 12.5% had multimorbidity. At baseline, the mean (±SD) age of cases was 42.32±10.69 years, whereas it was 38.41±8.23 years among controls. The median baseline CD4+ cell count was 184.50 cells/μL (IQR: 98.50 - 284.00 cells/μL) for cases and 177.0 cells/μL (IQR: 103.75 - 257.25 cells/μL) for controls. Post 6-months of highly active anti-retroviral therapy initiation, immunologic failure was 28.80% among cases and it was 16.25% among controls. An average increase of CD4+ cell count was 6.4 cells/μL per month among cases and 7.6 cells/μL per month among controls. The mean± SD score of health related quality of life among cases was 57.39 ±6.89, 73.52 ±13.22, 64.15±9.03, 81.37 ±8.31 and it was 71.74±21.64, 76.48±11.88, 67.25± 9.67, 81.53±8.08 among controls in physical health and symptoms, health concerns and mental distress, social and intimate relationships, treatment-related impact dimension respectively. Male sex [AOR, 3.51; 95% CI, 1.496 to 8.24; p=0.004], smoking history [AOR, 2.81; 95% CI, 1.072, to 7.342; p=0.036] and comorbidity with non-communicable chronic disease(s) [AOR 3.99; 95% CI, 1.604 to 9.916; p=0.003)] are independent predictors of immunologic failure. Conclusions and Recommendations: Chronic noncommunicable disease(s) have negative effects on the kinetics of CD4+ cell count and also have negative impact on quality of life among HIV-infected patients who initiated antiretroviral therapy. So integration of chronic noncommunicable disease-HIV collaborative activities will strengthen battle to control double burden of chronic illnesses.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 22 May 2017
Non-communicable disease comorbidities and treatment outcomes among people living with human immunodeficiency virus on highly active anti-retroviral therapy at Jimma University Specialized Hospital, South West Ethiopia: Nested case-control study
Research article · 16 Nov 2021
Stunting and its Associated Factors among Human Immunodeficiency Virus Positive Children Who Receiving Anti-retroviral Therapy in Northwest Ethiopia: Multicenter Study
Research article · 2014
Lipid Profile Derangements among Human Immunodeficiency Virus Infected Adults Receiving First Line Anti-Retroviral Therapy in Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: Comparative Cross-Sectional Study
Article · 2015
Myopathies Secondary To Anti-Retroviral Therapy In Human Immunodeficiency Virus Positive Patients: A Review
More from this journal
The newest in Journal of Virology & Antiviral Research.
Commentary · 19 Jun 2025
A Detailed Overview of Johne’s Disease: From Pathogenesis to Prevention and Control
Perspective · 19 Jun 2025
A Global Perspective on Brucellosis: Understanding the Disease and Diagnosis
Commentary · 19 Jun 2025
Understanding Bacterial Necrosis in Plants: Pathogenesis and Management Strategies
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Virology & Antiviral Research
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Tsegaye Melaku”
- BylineArticles whose byline prints “Girma Mamo”
- BylineArticles whose byline prints “Legese Chelkeba”
- BylineArticles whose byline prints “Tesfahun Chanie”

